title: Growth-inhibiting effect of intratumoral recombinant human tumor necrosis factor on an experimental model of primitive neuroectodermal tumor.
abstract: The effect of intratumoral administration of recombinant human tumor necrosis factor on an experimental model of primitive neuroectodermal neoplasia was studied. A clear inhibition of tumor growth was achieved by immunotherapy that consisted in intralesion injections of 100 micrograms of tumor necrosis factor daily, the first three days of each week, for a period of four weeks. At this time, tumor size was 2.21 +/- 0.66 cm2 (mean +/- standard deviation) in the treated group, versus 7.62 +/- 0.43 cm2 in the control group. These data support previous studies on the influence of tumor necrosis factor on the development of ethyl-nitrosourea-induced tumors, and suggest the potential usefulness of this cytokine in human primitive neuroectodermal neoplasms.
authors.affiliation: Laboratory of Experimental Neuro-oncology, Puerta de Hierro Clinic, Autonomous University, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Vaquero
authors.forename: M
authors.initials: M
authors.lastname: Zurita
authors.forename: S
authors.initials: S
authors.lastname: Oya
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D005038:Ethylnitrosourea; D006801:Humans; D016219:Immunotherapy, Adoptive; D018242:Neuroectodermal Tumors, Primitive / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D005038:Ethylnitrosourea